Abstract
Purpose :
To analyze real-world outcomes among patients with chronic non-infectious uveitis affecting the posterior segment (NIU-PS) receiving the 0.18 mg fluocinolone acetonide intravitreal implant (FAc).
Methods :
Eligible patients were ≥18 years of age, diagnosed with chronic NIU-PS, and did not have contraindications to the FAc implant. Effectiveness outcomes included recurrence of uveitis, change in optical coherence tomography (OCT) parameters, and visual acuity. Wilcoxon signed rank tests and linear mixed effect models were used to evaluate changes from baseline.
Results :
A total of 243 eyes from 182 patients received the FAc implant (mean age 63.2 years; 69% white; 65% female). In the 12 months prior to receiving the FAc implant, 84% of eyes had ≥1 reported recurrence of uveitis; in the 24 months following receipt of the implant, <10% had a reported recurrence. Through 24 months, 3.3% of eyes received more than one FAc implant (2.9% received two implants and 0.4% received three). Median central subfield thickness (CST), cube average thickness (CAT), and cube volume (CV) were 324 µm, 326 µm, and 9.06 mm3 at baseline, and 285 µm, 308 µm, and 8.45 mm3, respectively, at 24 months. Absolute reductions from baseline were statistically significant (for CST, P=0.013; for CAT, P<0.001; and for CV, P<0.001). Vitreous haze grade ≥0.5+ was present in 12% of eyes at baseline and 7% at 24 months. Median visual acuity (early treatment diabetic retinopathy study [ETDRS] letters converted from recorded Snellen values) improved from baseline (65.0) to 21 months (70.0) (P=0.001) and 24 months (70.0) (P=0.068). The proportion of eyes with a best-corrected visual acuity of 20/40 or better was stable from baseline (48%; 95% Confidence Interval [CI], [42, 54]) to 24 months (56%; 95% CI [50, 68]).
Conclusions :
Data from the CALM real-world registry study indicate efficacious control of NIU-PS with the FAc 0.18 mg implant, demonstrated by meaningful and consistent improvements in retinal thickness measurements and decreased uveitis recurrence through 24 months of follow up.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.